Won Il Jang1, Mi-Sook Kim2, Jung Sub Lim3, Hyung Jun Yoo4, Young Seok Seo1, Chul Ju Han5, Su Cheol Park5, Chul Seung Kay6, Myungsoo Kim6, Hong Seok Jang6, Dong Soo Lee6, Ah Ram Chang7, Hae Jin Park8. 1. Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea Cyberknife Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea mskim@kirams.re.kr. 3. Department of Pediatrics, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 4. Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea Cyberknife Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 5. Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 6. Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 7. Department of Radiation Oncology, Soonchunhyang University Hospital, Seoul, Republic of Korea. 8. Department of Radiation Oncology, Hanyang University Hospital, Seoul, Republic of Korea.
Abstract
BACKGROUND: The present study aimed to evaluate the effects of metformin on the clinical outcomes of patients receiving radiotherapy for inoperable hepatocellular carcinoma. PATIENTS AND METHODS: The medical records of 217 patients treated with stereotactic body or hypofractionated radiotherapy for inoperable hepatocellular carcinoma were reviewed. Patients were divided into the metformin group (n=19) and the non-metformin group (n=198), including those with diabetes (n=29), and those without (n=169). We performed a propensity score-matching analysis comparing the two groups. RESULTS: In the propensity score-matched cohort (n=76), the overall survival rate of the metformin group was higher than that of the non-metformin group (2-year, 76% vs. 37%, p=0.022). The adjusted Cox proportional hazards model revealed that metformin usage was a significant factor for mortality (adjusted hazard ratio=0.361; 95% confidence interval=0.139-0.935). CONCLUSION: The use of metformin in patients with hepatocellular carcinoma receiving radiotherapy was associated with higher overall survival. Copyright
BACKGROUND: The present study aimed to evaluate the effects of metformin on the clinical outcomes of patients receiving radiotherapy for inoperable hepatocellular carcinoma. PATIENTS AND METHODS: The medical records of 217 patients treated with stereotactic body or hypofractionated radiotherapy for inoperable hepatocellular carcinoma were reviewed. Patients were divided into the metformin group (n=19) and the non-metformin group (n=198), including those with diabetes (n=29), and those without (n=169). We performed a propensity score-matching analysis comparing the two groups. RESULTS: In the propensity score-matched cohort (n=76), the overall survival rate of the metformin group was higher than that of the non-metformin group (2-year, 76% vs. 37%, p=0.022). The adjusted Cox proportional hazards model revealed that metformin usage was a significant factor for mortality (adjusted hazard ratio=0.361; 95% confidence interval=0.139-0.935). CONCLUSION: The use of metformin in patients with hepatocellular carcinoma receiving radiotherapy was associated with higher overall survival. Copyright
Authors: Mohammad K Khan; Tahseen H Nasti; Zachary S Buchwald; Ralph R Weichselbaum; Stephen J Kron Journal: Cancer J Date: 2019 Mar/Apr Impact factor: 3.360
Authors: Elena Obrador; Rosario Salvador-Palmer; Juan I Villaescusa; Eduardo Gallego; Blanca Pellicer; José M Estrela; Alegría Montoro Journal: Antioxidants (Basel) Date: 2022-05-31
Authors: Mohammad Elsayed; William Wagstaff; Keywan Behbahani; Alexander Villalobos; Zachary Bercu; Bill S Majdalany; Mehmet Akce; David M Schuster; Hui Mao; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2021-07-26 Impact factor: 2.740